A systematic review of evidence‐based treatments for prurigo nodularis

[1]  S. Ständer,et al.  Prurigo Nodularis and Its Management. , 2018, Dermatologic clinics.

[2]  L. Misery,et al.  Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  S. Orlow,et al.  Rapid improvement of prurigo nodularis with cyclosporine treatment , 2018, Journal of the American Academy of Dermatology.

[4]  G. Yosipovitch,et al.  Successful Treatment of Epidermal Nevus-associated Pruritus with Topical Ketamine-Amitriptyline-Lidocaine. , 2018, Acta dermato-venereologica.

[5]  M. Maurer,et al.  Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant. , 2018, Acta dermato-venereologica.

[6]  C. Sommer,et al.  There is no functional small‐fibre neuropathy in prurigo nodularis despite neuroanatomical alterations , 2017, Experimental dermatology.

[7]  Y. Chan,et al.  Topical ketamine‐amitriptyline‐lidocaine for chronic pruritus: A retrospective study assessing efficacy and tolerability , 2017, Journal of the American Academy of Dermatology.

[8]  D. Jiménez-Gallo,et al.  Treatment of prurigo nodularis with lenalidomide , 2017, Dermatologic therapy.

[9]  J. Stewart,et al.  Anti–Interleukin‐31 Receptor A Antibody for Atopic Dermatitis , 2017, The New England journal of medicine.

[10]  S. Ständer,et al.  Chronic Pruritus in the Absence of Skin Disease: Pathophysiology, Diagnosis and Treatment , 2016, American Journal of Clinical Dermatology.

[11]  N. Osada,et al.  Intraepidermal Nerve Fibre Density is Decreased in Lesional and Inter-lesional Prurigo Nodularis and Reconstitutes on Healing of Lesions. , 2016, Acta dermato-venereologica.

[12]  S. Kwatra,et al.  Thalidomide for the treatment of chronic refractory pruritus. , 2016, Journal of the American Academy of Dermatology.

[13]  Michael Saco,et al.  Prurigo nodularis: Picking the right treatment. , 2015, The Journal of family practice.

[14]  M. Gilliet,et al.  Prurigo nodularis: retrospective study of 13 cases managed with methotrexate , 2014, Clinical and experimental dermatology.

[15]  T. Luger,et al.  Evaluation of the Antipruritic Effects of Topical Pimecrolimus in Non-Atopic Prurigo Nodularis: Results of a Randomized, Hydrocortisone-Controlled, Double-Blind Phase II Trial , 2013, Dermatology.

[16]  Ashima Sharma.  Oral Ketotifen and Topical Antibiotic Therapy in the Management of Pruritus in Prurigo Nodularis: A Randomized, Controlled, Single-Blind, Parallel Study , 2013, Indian journal of dermatology.

[17]  N. Osada,et al.  Gender differences in chronic pruritus: women present different morbidity, more scratch lesions and higher burden , 2013, The British journal of dermatology.

[18]  S. Ständer,et al.  Prurigo as a symptom of atopic and non‐atopic diseases: aetiological survey in a consecutive cohort of 108 patients , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[19]  A. Gaspari,et al.  Use of lenalidomide in treating refractory prurigo nodularis. , 2013, Journal of Drugs in Dermatology.

[20]  P. Bria,et al.  Treatment of prurigo nodularis with pregabalin , 2013, Journal of clinical pharmacy and therapeutics.

[21]  Murad Alam,et al.  Treatment of Refractory Prurigo Nodularis With Lenalidomide , 2016 .

[22]  T. P. Andersen,et al.  Thalidomide in 42 Patients with Prurigo Nodularis Hyde , 2011, Dermatology.

[23]  H. Ockenfels,et al.  UVB 308‐nm excimer light and bath PUVA: combination therapy is very effective in the treatment of prurigo nodularis , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[24]  S. Ständer,et al.  Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy , 2011, The British journal of dermatology.

[25]  A. Barbaud,et al.  Efficacy of thalidomide in the treatment of prurigo nodularis. , 2011, Acta dermato-venereologica.

[26]  Tomoko Mori,et al.  Increased expression of mRNAs for IL-4, IL-17, IL-22 and IL-31 in skin lesions of subacute and chronic forms of prurigo. , 2011, European journal of dermatology : EJD.

[27]  S. Chimenti,et al.  An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis , 2010, The Journal of dermatological treatment.

[28]  A. Wolkerstorfer,et al.  Excimer laser vs. clobetasol propionate 0·05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot , 2010, The British journal of dermatology.

[29]  B. Ladizinski,et al.  Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders. , 2010, Journal of drugs in dermatology : JDD.

[30]  T. Luger,et al.  Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy , 2010, PloS one.

[31]  T. Luger,et al.  Low density of sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis. , 2010, Journal of dermatological science.

[32]  G. Gencoglan,et al.  Therapeutic Hotline: Treatment of prurigo nodularis and lichen simplex chronicus with gabapentin , 2010, Dermatologic therapy.

[33]  R. Piccinno,et al.  Phototherapy of generalized prurigo nodularis , 2009, Clinical and experimental dermatology.

[34]  S. Chimenti,et al.  Different applications of monochromatic excimer light in skin diseases. , 2009, Photomedicine and laser surgery.

[35]  S. Ständer,et al.  Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: Results of a case series , 2008, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[36]  S. Doherty,et al.  A case series of 48 patients treated with thalidomide. , 2008, Journal of drugs in dermatology : JDD.

[37]  C. Heneghan,et al.  Levels of Evidence , 2006 .

[38]  J. Ring,et al.  Efficacy of UVA1 phototherapy in 230 patients with various skin diseases , 2008, Photodermatology, photoimmunology & photomedicine.

[39]  S. Chimenti,et al.  Monochromatic excimer light (308 nm) in the treatment of prurigo nodularis , 2008, Photodermatology, photoimmunology & photomedicine.

[40]  R. Tamagawa‐Mineoka,et al.  Narrow‐band ultraviolet B phototherapy in patients with recalcitrant nodular prurigo , 2007, The Journal of dermatology.

[41]  J. Leonard,et al.  Lenalidomide‐induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment‐naïve patients undergoing front‐line lenalidomide and dexamethasone therapy , 2007, British journal of haematology.

[42]  C. Chai,et al.  Treatment of idiopathic prurigo nodularis in Taiwanese patients with low‐dose thalidomide , 2007, The Journal of dermatology.

[43]  D. Gawkrodger,et al.  Nodular prurigo: metabolic diseases are a common association , 2007, Clinical and experimental dermatology.

[44]  E. Fauman,et al.  Pharmacology and mechanism of action of pregabalin: The calcium channel α2–δ (alpha2–delta) subunit as a target for antiepileptic drug discovery , 2007, Epilepsy Research.

[45]  T. Luger,et al.  Treatment of pruritic diseases with topical calcineurin inhibitors , 2006, Therapeutics and clinical risk management.

[46]  M. Steinhoff,et al.  IL-31: a new link between T cells and pruritus in atopic skin inflammation. , 2006, The Journal of allergy and clinical immunology.

[47]  S. Shumack,et al.  Prurigo nodularis: A review , 2005, The Australasian journal of dermatology.

[48]  S. Tyring,et al.  Thalidomide: dermatological indications, mechanisms of action and side‐effects , 2005, The British journal of dermatology.

[49]  E. Senba,et al.  The immunosuppressant FK506 activates capsaicin- and bradykinin-sensitive DRG neurons and cutaneous C-fibers , 2004, Neuroscience Research.

[50]  T. Maurer,et al.  Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. , 2004, Archives of dermatology.

[51]  P. Anand.  Capsaicin and menthol in the treatment of itch and pain: recently cloned receptors provide the key , 2003, Gut.

[52]  T. Luger,et al.  Antipruritische Wirkung von Pimecrolimus und Tacrolimus , 2003, Der Hautarzt.

[53]  R. Palmer,et al.  Phototherapy in nodular prurigo , 2003, Clincal and Experimental Dermatology.

[54]  P. Foley,et al.  Thalidomide experience of a major Australian teaching hospital , 2002, The Australasian journal of dermatology.

[55]  S. Ständer,et al.  Treatment of prurigo nodularis with topical capsaicin. , 2001, Journal of the American Academy of Dermatology.

[56]  H. Jacobi,et al.  CGRP‐immunoreactive nerves in prurigo nodularis – an exploration of neurogenic inflammation , 2000, Journal of cutaneous pathology.

[57]  C. Goh,et al.  Double-blind, right/left comparison of calcipotriol ointment and betamethasone ointment in the treatment of Prurigo nodularis. , 2000, Archives of dermatology.

[58]  H. Jacobi,et al.  Histamine‐containing mast cells and their relationship to NGFr‐immunoreactive nerves in prurigo nodularis: a reappraisal , 1998, Journal of cutaneous pathology.

[59]  I. Katayama,et al.  Topical vitamin D3 (tacalcitol) for steroid‐resistant prurigo , 1996, The British journal of dermatology.

[60]  K. Danno,et al.  Ultraviolet-B radiation suppresses mast cell degranulation induced by compound 48/80. , 1986, The Journal of investigative dermatology.

[61]  T. Ruzicka,et al.  Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. , 2017, The New England journal of medicine.

[62]  J. Zeldis,et al.  Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  T. Luger,et al.  Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. , 2009, Acta dermato-venereologica.

[64]  T. Dereli,et al.  Gabapentin for the treatment of recalcitrant chronic prurigo nodularis. , 2008, European journal of dermatology : EJD.

[65]  F. Sundler,et al.  Phototherapy reduces the number of epidermal and CGRP-positive dermal nerve fibres. , 2004, Acta dermato-venereologica.

[66]  J. Wallengren.  Prurigo , 2004, American journal of clinical dermatology.

[67]  S. Rajkumar,et al.  Management of thalidomide toxicity. , 2003, The journal of supportive oncology.

[68]  T. Luger,et al.  [Antipruritic effects of pimecrolimus and tacrolimus]. , 2003, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[69]  M. Just,et al.  Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis. , 1997, Dermatology.

[70]  C. Taylor.  Mechanisms of action of gabapentin. , 1997, Revue neurologique.

[71]  Taylor Cp.  Mechanisms of action of gabapentin. , 1997 .

[72]  N. Penneys,et al.  Demonstration by S-100 protein staining of increased numbers of nerves in the papillary dermis of patients with prurigo nodularis. , 1992, Journal of the American Academy of Dermatology.